00:37:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning PRLD 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-27 Kvartalsrapport 2023-Q3
2023-11-27 Extra Bolagsstämma 2023
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning PRLD 0.00 SEK
2023-05-11 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-21 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-08-04 Extra Bolagsstämma 2022
2022-05-23 Ordinarie utdelning PRLD 0.00 SEK
2022-05-20 Kvartalsrapport 2022-Q1
2022-05-20 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-23 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning PRLD 0.00 SEK
2021-05-05 Kvartalsrapport 2021-Q1
2021-05-05 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-21 Ordinarie utdelning PRLD 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma 2019
2019-05-10 Ordinarie utdelning PRLD 0.00 SEK
2018-11-20 Kvartalsrapport 2018-Q3
2018-08-28 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning PRLD 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-22 Ordinarie utdelning PRLD 0.00 SEK
2017-05-19 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2023-12-15 14:30:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Members of Prolight Diagnostics AB’s (publ) ("Prolight" or the "Company") board and management have committed to subscribe for units in the ongoing rights issue. In addition to previously communicated subscription commitments, Prolight has received additional commitments from Karl Bullen (COO) and Masoud Khayyami (Chairman of the Board). The Company has thereby obtained subscription commitments from the Company's board and management of approximately SEK 12.9 million, equivalent to 13.0 percent of the rights issue.

Advisors

Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.

For more information, please contact:

Ulf Bladin, CEO
E-mail: ub@prolightdx.com
Company website: www.prolightdx.com

About Prolight

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The Company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Prolight. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation for relevant individuals to subscribe to units in the Company will only take place through the Prospectus, which is available on the Company's website, www.prolightdx.com. The Swedish Financial Supervisory Authority's approval of the Prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. However, this press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Prolight. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be based solely on the information in the Prospectus. Therefore, an investor is recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.
The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Prolight have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or the regulations of the Spotlight Stock Market for issuers.